Acrux Limited Investor Presentation — August 2018

Document content

Forward looking statements

This presentation includes forward -looking statements that aresubject torisks and uncertainties .Such statements involve

known and unknown risks and important factors that may cause theactual results, performance orachievements ofAcrux

tobematerially different from thestatements inthis presentation .

Actual results could differ materially depending onfactors such asthe availability ofresources, the results ofclinical

studies, thetiming and effects ofregulatory actions, thestrength ofcompetition, theoutcome oflegal proceedings and

theeffectiveness ofpatent protection .

23FY18 Achievements

Full Year P&L and Cashflow

AgendaFY18 operational highlights

In FY18 Acrux expanded its high-potential portfolio of topical generic productsEXCELLENT R&D PROGRESS ON-SCHEDULE FDA APPLICATION HEALTHY CASH BALANCE

4▪Continued solid progress on our

portfolio of generic topical drugs

▪Engaged 4 contract manufacturing

organisations (CMO) for different

products in our pipeline

▪Achieved successful completion of

PK bioequivalence trial▪Acrux submitted its application to

market a generic version of

Jublia® in June 2018

▪On August 2ndthe application was

accepted for review by the FDA▪Net cash spend on operating

activities of ~A$5m in FY18

▪Cash reserves as at 30 June of

$28m in line with expectations

1. Source: US market by dosage form, IQVIA Q2, 2015 MAT. US market sales. US$; 2. Source: Market size for topically applied d rugs IQVIA Q3, 2017 MAT US$

Strategy recap: Topical generic portfolio

ADVANTAGES OF GENERIC STRATEGY

5•Fast development and low cost

•$3-4m to develop each generic

Preview truncated — download the full document for the complete content.